Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc (BRNS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
brns · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Barinthus Biotherapeutics plcYou BRNS | $30M | N/A | — | — |
 Aligos Therapeutics, Inc. ALGS | $32M | N/A | — | -$2.45 |
 CEL-SCI Corporation CVM | $10M | N/A | — | -$6.27 |
 INmune Bio, Inc. INMB | $34M | N/A | — | -$1.73 |
 Karyopharm Therapeutics Inc. KPTI | $198M | N/A | — | -$17.93 |
 Kezar Life Sciences, Inc. KZR | $54M | N/A | — | -$7.66 |
 Medicus Pharma Ltd. Common Stock MDCX | $7M | N/A | — | -$1.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Barinthus Biotherapeutics plc (BRNS) measures how much investors pay for each dollar of the company's trailing earnings. BRNS's current PE ratio of N/A is calculated by dividing its stock price of $0.74 by its TTM earnings per share of —.
Frequently asked questions
BRNS pe ratio · 6 questionsBRNS's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.74 and TTM EPS of —. Data sourced from Financial Modeling Prep via BRNS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Barinthus Biotherapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10